查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463908

肺癌基因組檢測醫學市場 - 全球產業規模、佔有率、趨勢、機會和預測，按技術、樣本類型、面板類型、最終用戶、地區和競爭細分2019-2029F

Lung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Sample Type, By Panel Type, By End-User, By Region and Competition2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球肺癌基因組檢測藥物市值為 18 億美元，預計到 2029 年預測期內將穩定成長，複合年成長率為 5.25%。這是一種複雜的疾病，可能具有多種遺傳和分子特徵，因此精確的診斷和治療對於改善患者的治療效果至關重要。近年來，腫瘤學領域在基因組檢測方面取得了重大進展。這種方法提供了對癌症基因組成的寶貴見解，並幫助腫瘤學家就治療策略做出更明智的決策。在肺癌方面，由於疾病的異質性，基因組檢測變得越來越重要。肺癌可大致分為兩種主要類型：非小細胞肺癌（NSCLC）和小細胞肺癌（SCLC）。在這些類別中，有許多亞型，每種亞型都有其獨特的遺傳標記。基因組測試能夠識別這些標記，從而實現更個人化和有效的治療方法。

肺癌仍然是全球健康問題，發生率很高。這就產生了對更精確的診斷和治療方案的巨大需求。與傳統化療相比，這些療法通常更有效且副作用更少。基因組測試可以識別哪些患者更有可能從免疫治療中受益，使其成為治療選擇的關鍵工具。它們可以分析患者血液中的循環腫瘤 DNA，提供有關疾病進展和治療反應的即時資訊。

主要市場促進因素

肺癌發生率上升正在推動全球肺癌基因組檢測藥物市場

醫療保健支出的增加正在推動全球肺癌基因組檢測藥物市場

主要市場挑戰

意識和可及性有限

成本限制

資料隱私和安全

標準化和監管

不斷變化的基因組景觀

抵制變革

道德兩難

主要市場趨勢

技術進步

細分市場洞察

技術洞察

樣本類型見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第4章：全球肺癌基因組檢測藥物市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按技術（聚合酶鍊式反應、新一代定序、螢光原位雜合技術等）
    • 按樣本類型（組織活體組織切片和液體活體組織切片）
    • 依Panel類型（多基因Panel和單基因Panel）
    • 按最終使用者（研究組織、醫院診所、診斷實驗室等）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 依技術
    • 依樣品類型
    • 按面板類型
    • 按最終用戶
    • 按地區

第 5 章：亞太地區肺癌基因組檢測藥物市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依技術
    • 依樣品類型
    • 按面板類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲肺癌基因組檢測藥物市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依技術
    • 依樣品類型
    • 按面板類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美肺癌基因組檢測藥物市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依技術
    • 依樣品類型
    • 按面板類型
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲肺癌基因組檢測藥物市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依技術
    • 依樣品類型
    • 按面板類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲肺癌基因組檢測藥物市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依技術
    • 依樣品類型
    • 按面板類型
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球肺癌基因組檢測藥物市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • QIAGEN NV
  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • CENTOGENE NV
  • BGI Genomics Co. Ltd.
  • CeGaT GmbH
  • Illumina Inc.
  • F. Hoffmann-La Roche Ltd

第 15 章：策略建議

第 16 章：關於我們免責聲明

簡介目錄
Product Code: 22690

Global Lung Cancer Genomic Testing Medicine Market was valued at USD 1.80 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Lung cancer is one of the most prevalent and deadly cancers worldwide. It is a complex disease that can have various genetic and molecular profiles, making precise diagnosis and treatment crucial for better patient outcomes. In recent years, the field of oncology has witnessed significant progress in the form of genomic testing.Genomic testing, also known as molecular profiling or genetic testing, is a method that analyzes the DNA and RNA of a cancer patient to identify specific genetic mutations or alterations in the tumor cells. This approach provides valuable insights into the genetic makeup of the cancer and helps oncologists make more informed decisions about treatment strategies. In the context of lung cancer, genomic testing has become increasingly important due to the heterogeneity of the disease. Lung cancer can be broadly categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Within these categories, there are numerous subtypes, each with its distinct genetic markers. Genomic testing enables the identification of these markers, allowing for a more personalized and effective treatment approach.

Lung cancer continues to be a global health concern, with a high incidence rate. This has created a substantial demand for more precise diagnostic and treatment options.Genomic testing has led to the development of targeted therapies that specifically address the genetic alterations present in an individual's lung cancer. These therapies are often more effective and have fewer side effects compared to traditional chemotherapy.The market for immunotherapies in lung cancer is expanding rapidly. Genomic testing can identify patients who are more likely to benefit from immunotherapy, making it a critical tool for treatment selection.Liquid biopsies, a non-invasive method of genomic testing, are gaining traction. They allow for the analysis of circulating tumor DNA in the patient's blood, providing real-time information about the disease's progression and treatment response.

Key Market Drivers

Rising Incidence of Lung Cancer is Driving the Global Lung Cancer Genomic Testing Medicine Market

Lung cancer is one of the most common and deadliest forms of cancer worldwide, accounting for a substantial number of cancer-related deaths each year. The alarming rise in the incidence of lung cancer has prompted a significant shift in the way this disease is diagnosed and treated. Genomic testing, which involves analyzing the genetic makeup of lung cancer cells, has emerged as a powerful tool in the fight against this devastating disease. As the incidence of lung cancer continues to grow, the global lung cancer genomic testing medicine market is witnessing unprecedented growth.Lung cancer remains a global health concern, and its incidence has been steadily increasing in recent years.

Smoking remains the leading cause of lung cancer, and despite significant efforts to reduce tobacco use, millions of people worldwide continue to smoke. This addictive habit continues to be a primary driver of lung cancer cases.Exposure to environmental carcinogens, such as radon gas, asbestos, and air pollution, has also been linked to an increased risk of lung cancer. As industrialization and urbanization progress, more people are exposed to these risk factors.Sedentary lifestyles, unhealthy diets, and increasing stress levels can contribute to the development of various health issues, including lung cancer. These lifestyle factors are becoming increasingly prevalent, especially in urban areas. Lung cancer is more common in older individuals, and as the global population ages, the number of lung cancer cases is expected to rise. In some regions, gender disparities exist, with lung cancer being more prevalent in men than in women. However, the incidence of lung cancer in women is also on the rise.

Increased Healthcare Spending is Driving the Global Lung Cancer Genomic Testing Medicine Market

One of the primary drivers behind the growth of the global lung cancer genomic testing medicine market is the substantial increase in healthcare spending worldwide. Governments, insurance companies, and private healthcare providers are investing heavily in the development and implementation of genomic testing for lung cancer patients.Greater funding and investment in healthcare infrastructure enable more hospitals and clinics to acquire advanced genomic testing technologies. This, in turn, allows a broader range of lung cancer patients to access these cutting-edge diagnostic and treatment options. Increased financial support from both public and private sectors fosters research and development in the field of genomic testing for lung cancer. This investment accelerates the discovery of new biomarkers and the development of targeted therapies, enhancing the effectiveness of treatment.With more healthcare spending dedicated to patient education and awareness campaigns, individuals are becoming increasingly informed about the benefits of genomic testing. As a result, they are more likely to request and participate in these tests, thus driving market growth.Many healthcare systems are expanding insurance coverage to include genomic testing for lung cancer. This ensures that a wider range of patients can afford these tests, further promoting their adoption.

The impact of increased healthcare spending on the global lung cancer genomic testing medicine market is significant. As more countries invest in research, technology, and healthcare infrastructure, the market is experiencing rapid growth. It is not only the developed nations that are driving this market but also emerging economies that are recognizing the importance of precision medicine in their healthcare systems. Moreover, collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions have intensified due to the heightened focus on lung cancer genomic testing. This collective effort is facilitating the development of innovative solutions and the commercialization of new products, leading to further market expansion.

Key Market Challenges

Limited Awareness and Accessibility

One of the foremost challenges in the lung cancer genomic testing market is the limited awareness among patients, healthcare providers, and even governments. Many people are unaware of the existence and importance of these tests, resulting in underutilization. Furthermore, access to genomic testing varies significantly across different regions, and not all patients have the opportunity to benefit from this advanced technology. Ensuring that patients and physicians are well-informed and expanding access to testing is crucial for market growth.

Cost Constraints

The cost of genomic testing can be a significant barrier for many patients and healthcare systems. High costs associated with test development, equipment, and analysis often translate to expensive tests, limiting their availability and affordability. To address this challenge, there is a need for ongoing research to reduce testing costs and for healthcare systems to consider reimbursing patients for these tests to make them more accessible.

Data Privacy and Security

Genomic testing generates a vast amount of sensitive patient data, including genetic information that has the potential for misuse if not adequately protected. Privacy concerns and data security challenges are a significant hurdle in the adoption of genomic testing. The industry needs to establish robust data protection protocols and regulatory frameworks to address these concerns and ensure patient trust.

Standardization and Regulation

The lung cancer genomic testing medicine market lacks standardized protocols for testing, reporting, and interpretation of results. This inconsistency can lead to discrepancies in the quality of testing and results, affecting patient care. Establishing comprehensive regulations and guidelines is essential to ensure the accuracy and reliability of genomic testing across the globe.

Evolving Genomic Landscape

The field of genomics is continually evolving, with new discoveries and technologies emerging at a rapid pace. This presents both an opportunity and a challenge for the lung cancer genomic testing market. Keeping up with the latest advancements in genomics and integrating them into clinical practice is vital, but it also requires ongoing investments in research, development, and training.

Resistance to Change

Changing traditional healthcare practices and introducing genomic testing into clinical workflows can be met with resistance from both healthcare providers and patients. There may be skepticism and reluctance to embrace new technologies and shift away from conventional treatment approaches. Effective educational and advocacy efforts are necessary to overcome this challenge.

Ethical Dilemmas

Genomic testing in lung cancer raises ethical questions regarding data use, informed consent, and potential discrimination based on genetic information. These ethical dilemmas must be addressed through transparent policies and guidelines to ensure that patients' rights and well-being are protected.

Key Market Trends

Technological Advancements

The global healthcare industry is experiencing a profound transformation, driven by technological advancements that are changing the way diseases are diagnosed, treated, and managed. In the realm of cancer care, one area where these innovations are making a significant impact is in the field of genomic testing for lung cancer. Lung cancer is a major global health concern, and as the second most common cancer, early detection and personalized treatment are essential for improving patient outcomes. The rise of genomic testing has opened new horizons in the battle against lung cancer, and it is propelling the global Lung Cancer Genomic Testing Medicine Market to new heights.

Next-Generation Sequencing (NGS) technologies have revolutionized genomic testing, enabling the comprehensive analysis of a patient's DNA. This has led to a deeper understanding of the genetic mutations responsible for lung cancer, allowing for more precise and personalized treatment plans.Liquid biopsies, which involve the analysis of blood samples, have gained traction as a non-invasive method for detecting lung cancer-related mutations. These tests are less invasive and can be performed more frequently, allowing for better monitoring of treatment response.Artificial Intelligence (AI) and machine learning are being used to analyse vast amounts of genomic data rapidly and accurately, assisting healthcare providers in identifying potential treatment options and predicting patient outcomes.As genomic testing identifies specific mutations, pharmaceutical companies are developing targeted therapies that can precisely attack these cancer-causing alterations. This approach minimizes side effects and maximizes the effectiveness of treatments.

Segmental Insights

Technology Insights

Basedon the category of Technology, Polymerase Chain Reaction emerged as the dominant player in the global market for Lung Cancer Genomic Testing Medicine in 2023.Polymerase Chain Reaction, or PCR, is a critical technology in the field of molecular biology and genomics. It allows for the amplification of specific DNA sequences, making it easier to detect mutations and alterations in the DNA of lung cancer cells. PCR has become a cornerstone in lung cancer genomic testing due to its precision, speed, and cost-effectiveness.PCR can detect even tiny amounts of DNA, making it highly sensitive and specific in identifying genetic mutations in lung cancer. This precision is crucial in determining the most suitable treatment options for each patient.

PCR is a rapid technique that can generate results in a matter of hours, allowing healthcare providers to make timely decisions about patient care. This speed is especially important in the fast-paced world of cancer treatment.PCR is a cost-effective method compared to other genomic testing technologies. This affordability ensures that more patients can access and benefit from genomic testing, contributing to better treatment outcomes.The information derived from PCR can guide oncologists in tailoring treatments to a patient's specific genetic profile. This personalized approach often results in better treatment responses and fewer side effects.PCR is not only useful in the initial diagnosis but also in monitoring disease progression and response to treatment. By regularly testing for genetic changes, clinicians can adapt treatment strategies as needed.

Sample type Insights

The Tissue Biopsy segment is projected to experience rapid growth during the forecast period. Tissue biopsy, which involves extracting a small sample of lung tissue for analysis, has emerged as the primary method for conducting genomic testing in lung cancer cases. Tissue biopsy provides a comprehensive view of the genetic mutations and alterations present in a patient's tumor. This comprehensive analysis enables oncologists to make more accurate and personalized treatment decisions. Tissue biopsy is known for its accuracy and reliability in identifying genomic alterations. It is considered the gold standard for detecting specific mutations and guiding treatment choices. Lung cancer is a highly heterogeneous disease, with genetic changes occurring at different sites within the tumor. Tissue biopsy allows for the assessment of this intra-tumor heterogeneity, providing a more accurate representation of the genetic landscape of the cancer. Genomic testing from tissue biopsy can identify predictive biomarkers, such as EGFR mutations or ALK rearrangements, which can guide the selection of targeted therapies. This approach leads to more successful treatment outcomes and fewer adverse effects.

Regional Insights

North America emerged as the dominant region in the global Lung Cancer Genomic Testing Medicine market in 2023, holding the largest market share in terms of value. North America, particularly the United States and Canada, has been at the forefront of lung cancer genomic testing medicine research and innovation. World-class research institutions, medical centers, and pharmaceutical companies in the region have invested heavily in the development of cutting-edge technologies and therapies. This has contributed to North America's leadership in the field. The region boasts a significant presence of advanced technology companies and genomic sequencing centers that offer state-of-the-art equipment and expertise in genomic testing. This accessibility to cutting-edge technology has allowed North American healthcare providers to offer comprehensive genomic testing services to lung cancer patients.

Key Market Players

QIAGEN NV

Agilent Technologies Inc.

Thermo Fisher Scientific Inc.

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

CENTOGENE N.V.

BGI Genomics Co. Ltd.

CeGaT GmbH

Illumina Inc.

F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Medicine Market,By Technology:

  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • Fluorescence In-Situ Hybridization
  • Others

Lung Cancer Genomic Testing Medicine Market,By Sample Type:

  • Tissue Biopsy
  • Liquid Biopsy

Lung Cancer Genomic Testing Medicine Market,By Panel Type:

  • Multi-Gene Panel
  • Single-Gene Panel

Lung Cancer Genomic Testing Medicine Market,By End-User:

  • Research Organization
  • Hospitals Clinics
  • Diagnostic Laboratories
  • Others

Lung Cancer Genomic Testing Medicine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Lung Cancer Genomic Testing Medicine Market Outlook

  • 4.1.Market Size Forecast
    • 4.1.1.By Value
  • 4.2.Market Share Forecast
    • 4.2.1.By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and Others)
    • 4.2.2.By Sample Type (Tissue Biopsy and Liquid Biopsy)
    • 4.2.3.By Panel Type (Multi-Gene Panel and Single-Gene Panel)
    • 4.2.4.By End-User (Research Organization, Hospitals Clinics, Diagnostic Laboratories, Others)
    • 4.2.5.By Region
    • 4.2.6.By Company (2023)
  • 4.3.Market Map
    • 4.3.1.By Technology
    • 4.3.2.By Sample Type
    • 4.3.3.By Panel Type
    • 4.3.4.By End-User
    • 4.3.5.By Region

5.Asia Pacific Lung Cancer Genomic Testing Medicine Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Technology
    • 5.2.2.By Sample Type
    • 5.2.3.By Panel Type
    • 5.2.4.By End-User
    • 5.2.5.By Country
  • 5.3.Asia Pacific: Country Analysis
    • 5.3.1.China Lung Cancer Genomic Testing Medicine Market Outlook
      • 5.3.1.1.Market Size Forecast
        • 5.3.1.1.1.By Value
      • 5.3.1.2.Market Share Forecast
        • 5.3.1.2.1.By Technology
        • 5.3.1.2.2.By Sample Type
        • 5.3.1.2.3.By Panel Type
        • 5.3.1.2.4.By End-User
    • 5.3.2.India Lung Cancer Genomic Testing Medicine Market Outlook
      • 5.3.2.1.Market Size Forecast
        • 5.3.2.1.1.By Value
      • 5.3.2.2.Market Share Forecast
        • 5.3.2.2.1.By Technology
        • 5.3.2.2.2.By Sample Type
        • 5.3.2.2.3.By Panel Type
        • 5.3.2.2.4.By End-User
    • 5.3.3.Australia Lung Cancer Genomic Testing Medicine Market Outlook
      • 5.3.3.1.Market Size Forecast
        • 5.3.3.1.1.By Value
      • 5.3.3.2.Market Share Forecast
        • 5.3.3.2.1.By Technology
        • 5.3.3.2.2.By Sample Type
        • 5.3.3.2.3.By Panel Type
        • 5.3.3.2.4.By End-User
    • 5.3.4.Japan Lung Cancer Genomic Testing Medicine Market Outlook
      • 5.3.4.1.Market Size Forecast
        • 5.3.4.1.1.By Value
      • 5.3.4.2.Market Share Forecast
        • 5.3.4.2.1.By Technology
        • 5.3.4.2.2.By Sample Type
        • 5.3.4.2.3.By Panel Type
        • 5.3.4.2.4.By End-User
    • 5.3.5.South Korea Lung Cancer Genomic Testing Medicine Market Outlook
      • 5.3.5.1.Market Size Forecast
        • 5.3.5.1.1.By Value
      • 5.3.5.2.Market Share Forecast
        • 5.3.5.2.1.By Technology
        • 5.3.5.2.2.By Sample Type
        • 5.3.5.2.3.By Panel Type
        • 5.3.5.2.4.By End-User

6.Europe Lung Cancer Genomic Testing Medicine Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Technology
    • 6.2.2.By Sample Type
    • 6.2.3.By Panel Type
    • 6.2.4.By End-User
    • 6.2.5.By Country
  • 6.3.Europe: Country Analysis
    • 6.3.1.France Lung Cancer Genomic Testing Medicine Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Technology
        • 6.3.1.2.2.By Sample Type
        • 6.3.1.2.3.By Panel Type
        • 6.3.1.2.4.By End-User
    • 6.3.2.Germany Lung Cancer Genomic Testing Medicine Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Technology
        • 6.3.2.2.2.By Sample Type
        • 6.3.2.2.3.By Panel Type
        • 6.3.2.2.4.By End-User
    • 6.3.3.Spain Lung Cancer Genomic Testing Medicine Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Technology
        • 6.3.3.2.2.By Sample Type
        • 6.3.3.2.3.By Panel Type
        • 6.3.3.2.4.By End-User
    • 6.3.4.Italy Lung Cancer Genomic Testing Medicine Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Technology
        • 6.3.4.2.2.By Sample Type
        • 6.3.4.2.3.By Panel Type
        • 6.3.4.2.4.By End-User
    • 6.3.5.United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Technology
        • 6.3.5.2.2.By Sample Type
        • 6.3.5.2.3.By Panel Type
        • 6.3.5.2.4.By End-User

7.North America Lung Cancer Genomic Testing Medicine Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Technology
    • 7.2.2.By Sample Type
    • 7.2.3.By Panel Type
    • 7.2.4.By End-User
    • 7.2.5.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Lung Cancer Genomic Testing Medicine Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Technology
        • 7.3.1.2.2.By Sample Type
        • 7.3.1.2.3.By Panel Type
        • 7.3.1.2.4.By End-User
    • 7.3.2.Mexico Lung Cancer Genomic Testing Medicine Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Technology
        • 7.3.2.2.2.By Sample Type
        • 7.3.2.2.3.By Panel Type
        • 7.3.2.2.4.By End-User
    • 7.3.3.Canada Lung Cancer Genomic Testing Medicine Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Technology
        • 7.3.3.2.2.By Sample Type
        • 7.3.3.2.3.By Panel Type
        • 7.3.3.2.4.By End-User

8.South America Lung Cancer Genomic Testing Medicine Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Technology
    • 8.2.2.By Sample Type
    • 8.2.3.By Panel Type
    • 8.2.4.By End-User
    • 8.2.5.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Lung Cancer Genomic Testing Medicine Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Technology
        • 8.3.1.2.2.By Sample Type
        • 8.3.1.2.3.By Panel Type
        • 8.3.1.2.4.By End-User
    • 8.3.2.Argentina Lung Cancer Genomic Testing Medicine Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Technology
        • 8.3.2.2.2.By Sample Type
        • 8.3.2.2.3.By Panel Type
        • 8.3.2.2.4.By End-User
    • 8.3.3.Colombia Lung Cancer Genomic Testing Medicine Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Technology
        • 8.3.3.2.2.By Sample Type
        • 8.3.3.2.3.By Panel Type
        • 8.3.3.2.4.By End-User

9.Middle East and Africa Lung Cancer Genomic Testing Medicine Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Technology
    • 9.2.2.By Sample Type
    • 9.2.3.By Panel Type
    • 9.2.4.By End-User
    • 9.2.5.By Country
  • 9.3.MEA: Country Analysis
    • 9.3.1.South Africa Lung Cancer Genomic Testing Medicine Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Technology
        • 9.3.1.2.2.By Sample Type
        • 9.3.1.2.3.By Panel Type
        • 9.3.1.2.4.By End-User
    • 9.3.2.Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Technology
        • 9.3.2.2.2.By Sample Type
        • 9.3.2.2.3.By Panel Type
        • 9.3.2.2.4.By End-User
    • 9.3.3.UAE Lung Cancer Genomic Testing Medicine Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Technology
        • 9.3.3.2.2.By Sample Type
        • 9.3.3.2.3.By Panel Type
        • 9.3.3.2.4.By End-User

10.Market Dynamics

  • 10.1.Drivers
  • 10.2.Challenges

11.Market Trends Developments

  • 11.1.Recent Developments
  • 11.2.Product Launches
  • 11.3.Mergers Acquisitions

12.Global Lung Cancer Genomic Testing Medicine Market: SWOT Analysis

13.Porter's Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Product

14.Competitive Landscape

  • 14.1.QIAGEN NV
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Product Services
    • 14.1.5.Financials (In case of listed)
    • 14.1.6.Recent Developments
    • 14.1.7.SWOT Analysis
  • 14.2.Agilent Technologies Inc.
  • 14.3.Thermo Fisher Scientific Inc.
  • 14.4.Quest Diagnostics Incorporated
  • 14.5.Laboratory Corporation of America Holdings
  • 14.6.CENTOGENE N.V.
  • 14.7.BGI Genomics Co. Ltd.
  • 14.8.CeGaT GmbH
  • 14.9.Illumina Inc.
  • 14.10.F. Hoffmann-La Roche Ltd

15.Strategic Recommendations

16.About Us Disclaimer